Bellwave-011: A phase 3 trial of nemabrutinib in people with chronic lymphocytic leukaemia or small lymphocytic lymphoma

This trial is testing the medication nemabrutinib (MK-1026) in people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT06136559

Trial aim and background  

The aim of this trial is to find out how effective the medication nemabrutinib (MX-1026) is when given to patients with CLL or SLL who have not yet received any treatment. 

Participants in the trial will either receive nemabrutinib or, ibrutinib or acalabrutinib. They will not be able to chose which medication they receive.

It aims to test how effective it is compared to current treatment (ibrutinib or acalabrutinib) at achieving remission, and also how long it is effective for.

Nemabrutinib is a type of targeted treatment called a BTK inhibitor. It blocks to a protein called Bruton’s tyrosine kinase. This stops the B cells from growing out of control. Nemabrutinib is different from other BTK inhibitors in that it can also bind to some other proteins, and can bind to some common mutations. These mutations often make other BTK inhibitors ineffective long term.

Who can enter 

People with CLL or SLL who have not received any previous treatment may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • The Churchill Hospital, Oxford
  • GenesisCare, Cambridge

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06136559

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.